|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0005682,
umls-concept:C0015295,
umls-concept:C0017262,
umls-concept:C0185117,
umls-concept:C0332281,
umls-concept:C0441994,
umls-concept:C1136197,
umls-concept:C1140680,
umls-concept:C1417745,
umls-concept:C1882417,
umls-concept:C2266395,
umls-concept:C2911684
|
|
pubmed:issue |
5
|
|
pubmed:dateCreated |
2007-3-2
|
|
pubmed:abstractText |
NRH:quinone oxidoreductase 2 (NQO2) is a homologue of NAD(P)H:quinone oxidoreductase 1 (NQO1). Despite 54% homology with human NQO1, NQO2 has little endogenous enzymatic activity. However, NQO2 has potential as a therapeutic target because the addition of the nonbiogenic electron donor dihydronicotinamide riboside (NRH) selectively potentiates the bioactivation of the alkylating agent tretazicar (CB 1954). The NQO activity of ovarian and bladder tumors was determined and the effect of NQO polymorphisms on NQO activity was investigated.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Mar
|
|
pubmed:issn |
1078-0432
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
1
|
|
pubmed:volume |
13
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1584-90
|
|
pubmed:dateRevised |
2007-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:17332305-Female,
pubmed-meshheading:17332305-Humans,
pubmed-meshheading:17332305-NAD(P)H Dehydrogenase (Quinone),
pubmed-meshheading:17332305-Niacinamide,
pubmed-meshheading:17332305-Ovarian Neoplasms,
pubmed-meshheading:17332305-Polymorphism, Restriction Fragment Length,
pubmed-meshheading:17332305-Polymorphism, Single Nucleotide,
pubmed-meshheading:17332305-Quinone Reductases,
pubmed-meshheading:17332305-Reverse Transcriptase Polymerase Chain Reaction,
pubmed-meshheading:17332305-Urinary Bladder Neoplasms
|
|
pubmed:year |
2007
|
|
pubmed:articleTitle |
NAD(P)H:quinone oxidoreductase 1 and nrh:quinone oxidoreductase 2 activity and expression in bladder and ovarian cancer and lower NRH:quinone oxidoreductase 2 activity associated with an NQO2 exon 3 single-nucleotide polymorphism.
|
|
pubmed:affiliation |
Northern Institute for Cancer Research, Medical School, University of Newcastle upon Tyne, Newcastle upon Tyne, United Kingdom. david.jamieson@ncl.ac.uk
|
|
pubmed:publicationType |
Journal Article
|
